IL159926A0 - Aminoisoxazole derivatives active as kinase inhibitors - Google Patents

Aminoisoxazole derivatives active as kinase inhibitors

Info

Publication number
IL159926A0
IL159926A0 IL15992602A IL15992602A IL159926A0 IL 159926 A0 IL159926 A0 IL 159926A0 IL 15992602 A IL15992602 A IL 15992602A IL 15992602 A IL15992602 A IL 15992602A IL 159926 A0 IL159926 A0 IL 159926A0
Authority
IL
Israel
Prior art keywords
kinase inhibitors
derivatives active
aminoisoxazole derivatives
aminoisoxazole
active
Prior art date
Application number
IL15992602A
Other languages
English (en)
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of IL159926A0 publication Critical patent/IL159926A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15992602A 2001-08-06 2002-07-29 Aminoisoxazole derivatives active as kinase inhibitors IL159926A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92175101A 2001-08-06 2001-08-06
PCT/EP2002/008634 WO2003013517A1 (en) 2001-08-06 2002-07-29 Aminoisoxazole derivatives active as kinase inhibitors

Publications (1)

Publication Number Publication Date
IL159926A0 true IL159926A0 (en) 2004-06-20

Family

ID=25445927

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15992602A IL159926A0 (en) 2001-08-06 2002-07-29 Aminoisoxazole derivatives active as kinase inhibitors

Country Status (18)

Country Link
US (1) US20050059657A1 (cs)
EP (1) EP1435948A1 (cs)
JP (1) JP2005501073A (cs)
KR (1) KR20040030941A (cs)
CN (1) CN1549714A (cs)
AU (1) AU2002342607B2 (cs)
BR (1) BR0211742A (cs)
CA (1) CA2455631A1 (cs)
CO (1) CO5640104A2 (cs)
CZ (1) CZ2004168A3 (cs)
EA (1) EA006769B1 (cs)
IL (1) IL159926A0 (cs)
MX (1) MXPA04000920A (cs)
NO (1) NO20040511L (cs)
NZ (1) NZ530782A (cs)
PL (1) PL368403A1 (cs)
WO (1) WO2003013517A1 (cs)
ZA (1) ZA200400347B (cs)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04002785A (es) * 2001-09-24 2004-07-29 Elan Pharm Inc Aminas sustituidas para tratamiento de enfermedad de alzheimer.
RU2006106920A (ru) 2003-08-06 2007-09-20 Синомикс Инк. (Us) Гетеро-олигомерные вкусовые рецепторы t1r, клеточные линии, которые экспрессируют указанные рецепторы и вкусовые соединения
JP2007512255A (ja) 2003-11-13 2007-05-17 アンビット バイオサイエンシス コーポレーション キナーゼ調節因子としての尿素誘導体
WO2005061519A1 (en) * 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
JP2007533753A (ja) * 2004-04-23 2007-11-22 タケダ サン ディエゴ インコーポレイテッド インドール誘導体及びキナーゼ阻害剤としてのその使用
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
MXPA06013022A (es) * 2004-05-12 2007-01-23 Squibb Bristol Myers Co Antagonistas de urea de receptor p2y1 utiles en el tratamiento de condiciones tromboticas.
JP2008510734A (ja) * 2004-08-18 2008-04-10 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
EP1812439B2 (en) * 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
ATE499370T1 (de) 2005-01-19 2011-03-15 Bristol Myers Squibb Co 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3- aminderivate und verwandte verbindungen als p2y1- rezeptor-hemmer zur behandlung thromboembolischer erkrankungen
MX2007009388A (es) 2005-02-04 2007-09-25 Senomyx Inc Compuestos que comprenden porciones heteroarilo unidas y su uso como modificadores del sabor unami, saborizantes y mejoradores del sabor para composiciones comestibles.
US8952176B2 (en) 2005-06-07 2015-02-10 Shionogi & Co., Ltd. Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity
TW200715993A (en) 2005-06-15 2007-05-01 Senomyx Inc Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers
US7728008B2 (en) 2005-06-27 2010-06-01 Bristol-Myers Squibb Company N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7714002B2 (en) 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
ES2352796T3 (es) 2005-06-27 2011-02-23 Bristol-Myers Squibb Company Antagonistas cíclicos unidos a c del receptor p2y1 útiles en el tratamiento de afecciones trombóticas.
DE602006020871D1 (de) 2005-06-27 2011-05-05 Bristol Myers Squibb Co Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
EP1772449A1 (en) * 2005-10-05 2007-04-11 Bayer CropScience S.A. New N-alkyl-heterocyclyl carboxamide derivatives
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2625301A1 (en) * 2005-10-11 2007-04-19 F. Hoffmann-La Roche Ag Isoxazole derivatives
JP2009514924A (ja) * 2005-11-09 2009-04-09 エフ．ホフマン−ラ ロシュ アーゲー ３−アリール−イソオキサゾール−４−カルボニル−ベンゾフラン誘導体
KR101394245B1 (ko) * 2005-12-30 2014-05-14 에스케이바이오팜 주식회사 아이속사졸 유도체 및 이의 용도
EP2006286A4 (en) 2006-03-30 2010-04-07 Shionogi & Co ISOXAZOLE DERIVATIVE AND ISOTHIAZONE DERIVATIVITY WITH ANTICIPATING EFFECT ON 11 TYPE I BETA HYDROXYSTEROIDDEHYDROGENASE
DK3235811T3 (en) 2006-04-21 2018-11-12 Senomyx Inc PROCEDURE FOR THE PREPARATION OF OXALAMIDS
BRPI0712862A2 (pt) * 2006-06-08 2012-12-18 Lilly Co Eli carboxamidas substituìdas
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
EA200970361A1 (ru) 2006-10-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед Ингибиторы киназы
WO2008046072A2 (en) * 2006-10-13 2008-04-17 The Board Of Regents Of The University Of Texas System Chemical inducers of neurogenesis
US8193225B2 (en) 2006-10-13 2012-06-05 The Board Of Regents Of The University Of Texas System Isoxazole amides, derivatives and methods of chemical induction of neurogenesis
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
ATE539078T1 (de) 2007-06-29 2012-01-15 Sk Holdings Co Ltd Isoxazolderivate enthaltende pharmazeutische zusammensetzung zur prävention und behandlung von restenose
JP5411141B2 (ja) 2007-09-10 2014-02-12 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
WO2009076454A2 (en) * 2007-12-12 2009-06-18 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2010027875A2 (en) * 2008-08-27 2010-03-11 Calcimedica Inc. Compounds that modulate intracellular calcium
US8524763B2 (en) 2008-09-22 2013-09-03 Calcimedica, Inc. Inhibitors of store operated calcium release
US8618307B2 (en) 2009-09-16 2013-12-31 Calcimedica, Inc. Compounds that modulate intracellular calcium
CN103242256A (zh) * 2013-05-21 2013-08-14 苏州科捷生物医药有限公司 一种3-胺甲基-异噁唑盐酸盐的合成方法
KR101646180B1 (ko) * 2014-09-22 2016-08-05 한양대학교 에리카산학협력단 N-(5-아릴아미도-2-메틸페닐)-5-메틸이소옥사졸-4-카복스아미드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 fms 키나아제 저해제
BR112021007602A2 (pt) * 2018-10-22 2021-07-27 Assembly Biosciences, Inc. compostos de heteroaril carboxamida de 5 membros para tratamento de hbv
CN113069451B (zh) * 2021-04-02 2022-08-09 苏州大学 一种吡咯-2-磺酰胺化合物的制备方法及其在制备抗肿瘤药物中的应用
CN116283946B (zh) * 2023-03-27 2024-05-07 武汉工程大学 5-(n-取代吲哚-5-基)异噁唑-3-甲酸衍生物及其合成方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1108397A (en) * 1965-08-18 1968-04-03 Geigy Ag J R 5-nitro-2-furyl-isoxazoles
GB1162257A (en) * 1965-09-22 1969-08-20 Danippon Pharmaceutical Co Ltd 3-(5-Nitro-2-Furyl) Isoxazole Derivatives and methods of preparation thereof
US3631169A (en) * 1966-09-22 1971-12-28 Dainippon Pharmaceutical Co 3-(5-nitro-2-furyl)isoxazoline derivatives
US3522252A (en) * 1968-04-03 1970-07-28 R & L Molecular Research Ltd Basic esters of 5-alkanoylamino-3-(5'-nitrofur - 2' - yl)isoxazole - 4 - carboxylic acid
GB1250219A (cs) * 1968-12-06 1971-10-20
US5968737A (en) * 1996-11-12 1999-10-19 The University Of Mississippi Method of identifying inhibitors of glutathione S-transferase (GST) gene expression
BR0013551A (pt) * 1999-08-13 2003-06-17 Vertex Pharma Inibidores de cinases n-terminal cjun (jnk) e outras cinases de proteìnas
WO2002022610A1 (en) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Isoxazoles and their use as inhibitors of erk

Also Published As

Publication number Publication date
JP2005501073A (ja) 2005-01-13
PL368403A1 (en) 2005-03-21
WO2003013517A1 (en) 2003-02-20
CZ2004168A3 (cs) 2004-05-12
NO20040511L (no) 2004-03-23
CA2455631A1 (en) 2003-02-20
US20050059657A1 (en) 2005-03-17
MXPA04000920A (es) 2004-04-02
NZ530782A (en) 2005-11-25
BR0211742A (pt) 2004-08-24
AU2002342607B2 (en) 2006-10-19
KR20040030941A (ko) 2004-04-09
EA006769B1 (ru) 2006-04-28
EP1435948A1 (en) 2004-07-14
CO5640104A2 (es) 2006-05-31
CN1549714A (zh) 2004-11-24
ZA200400347B (en) 2005-03-30
EA200400289A1 (ru) 2004-06-24

Similar Documents

Publication Publication Date Title
IL159926A0 (en) Aminoisoxazole derivatives active as kinase inhibitors
IL165515A0 (en) Bisindolyl-maleimid derivatives as kinase inhibitors
HUP0202713A3 (en) Pteridinones as kinase inhibitors
SI1686119T1 (sl) Derivati pirimidin-5-ona kot inhibitorji ldl-pla2
IL151104A0 (en) Kinase inhibitors
AU2001237041A1 (en) Kinase inhibitors
AU2002303892A1 (en) 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
IL182428A0 (en) Indolylmaleimide derivatives as protein kinase c inhibitors
AU3116602A (en) Pyrazole compounds useful as protein kinase inhibitors
HK1058356A1 (en) Pyrazole compounds useful as protein kinase inhibitors
AU2003271566A8 (en) Pyrrolopyrazines as kinase inhibitors
IL161516A0 (en) Benzimidazoles useful as protein kinase inhibitors
AU6117801A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
HUP0401641A3 (en) Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors
AU2002305168A1 (en) Triazinyl acrylamide derivatives as kinase inhibitors
AU2002246255A1 (en) Jun kinase inhibitors
AU2002334208A1 (en) 2-aminoquinolone derivatives for use as impdh inhibitors
SI1296981T1 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors